Urinary Tract Infection, Vesicoureteral Reflux (VUR)
Conditions
Keywords
Vesicoureteral Reflux (VUR), Complicated Urinary Tract Infection, Vantris, Polyacrylate Polyalcohol Copolymer
Brief summary
Endoscopic correction of VUR has gained its popularity due to its less invasiveness, associated low morbidity and short hospital stay. Although short term follow-up had justified their efficacy; however, long term recurrence and complications following endoscopic correction were also being reported in the literatures (6). Currently, there are insufficient evidences on the efficacy and safety of biocompatible tissue augmenting materials used for endoscopic correction of VUR; particularly on the new tissue bulking agents. (6) Polyacrylate polyalcohol copolymer (PPC)-Vantris ® (Promedon, Cordoba, Argentina) is the newest tissue augmenting biocompatible Acrylics used for endoscopic correction of VUR.
Interventions
None listed
Sponsors
St. Luke's Medical Center, Philippines
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 5 Years
Healthy volunteers
No
Inclusion criteria
* Included patients for the study were only those who had 1- 3months and \>1year post-treatment follow-up study with voiding cystourethrogram (VCUG), kidney ultrasound, dimercaptosuccinic acid(DMSA) renal scan, and urine culture.
Exclusion criteria
* Excluded cases were patients who had VUR grade 1 and grade 5, no complete follow-up work ups, concomitant neurogenic bladder, anatomical malformation of the urinary tract (obstruction, complete duplicated pelvocaliceal system), previous surgical or endoscopic procedures, and suspected or confirmed dysfunctional voiding by clinical findings or abnormal results (irregular bladder wall, diverticulum) on VCUG or urodynamic study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Treatment success | 3 months, 1 year | Rate of complete resolution of VUR on follow-up VCUG at 3 months and 1 year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of renal scar development | at 3 months, 1 year | The rate of Renal scarring is defined as consistent decreased tracer activity noted in follow-up DMSA scan. |
| Length of VUR treatment related hospital stay | 1 year | Number of hospital days incurred related to VUR treatment, such as hospital admission on treatment period, recovery period, and subsequent admissions for complicated UTI secondary to VUR. |
| Rate of failed treatment response | 3 months, 1 year | Rate of VUR with resoultion noted on 3 month follow-up; however, VUR noted on 1 year VCUG follow-up. Failed treatment defined as persistent VUR or VUR grade progressed despite treatment. |
Countries
Philippines
Outcome results
None listed